Outcomes of toll-like receptors’ antagonism in steroid-resistant optic neuritis; a pilot study

Sudhalkar, Aditya; Khamar, Mayuri; Khamar, Bakulesh

doi:10.1007/s00417-011-1896-1

Cited by 5 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on its relatively low cost and good safety profile, it was studied in eight patients with steroid-refractory ON. All six who completed follow-up showed visual improvement in this uncontrolled trial,39 and further research into this therapy has been suggested.…”

Section: Demyelinating Onmentioning

confidence: 78%

Current options for the treatment of optic neuritis

Pula¹,

MacDonald²

2012

OPTH

View full text Add to dashboard Cite

Optic neuritis can be defined as typical (associated with multiple sclerosis, improving independent of steroid treatment), or atypical (not associated with multiple sclerosis, steroid-dependent improvement). Causes of atypical optic neuritis include connective tissue diseases (eg, lupus), vasculitis, sarcoidosis, or neuromyelitis optica. In this manuscript, updated treatment options for both typical and atypical optic neuritis are reviewed. Conventional treatments, such as corticosteroids, therapeutic plasma exchange, and intravenous immunoglobulin therapy are all discussed with commentary regarding evidence-based outcomes. Less commonly used treatments and novel purported therapies for optic neuritis are also reviewed. Special scenarios in the treatment of optic neuritis – pediatric optic neuritis, acute demyelinating encephalomyelitis, and optic neuritis occurring during pregnancy – are specifically examined.

show abstract

Section: Demyelinating Onmentioning

confidence: 78%

Current options for the treatment of optic neuritis

Pula¹,

MacDonald²

2012

OPTH

View full text Add to dashboard Cite

show abstract

“…Safety of addition of 0.6 mL of Mw to standard of treatment observed in this case series is in accordance with previous reports. 12 , 13 It also paves way for evaluating Mw via the IV route in a larger study.…”

Section: Discussionmentioning

confidence: 99%

“…The highest dose administered so far by intradermal route is 0.3 mL/day compared to a dose as high as 5.0 mL/day by IV route. 12 , 13 IV administration of Mw in the management of gram-negative sepsis or COVID-19 is not known. In this case series, we present retrospective analysis of the administration of 0.6 mL/day of Mw by IV route in the critically ill patients of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Early Experience of High-dose Intravenous Mycobacterium w in Critically Ill Patients of COVID-19

Patel¹,

Patel²,

Shah³

et al. 2021

Indian Journal of Critical Care Medicine

View full text Add to dashboard Cite

A bstract Background Immune dysregulation is one of the main reasons for mortality and morbidity in coronavirus disease 2019 (COVID-19). Mycobacterium w (Mw) is recently approved for gram-negative sepsis. Moreover, it is also found effective in COVID-19 patients in previous studies. The traditional route of administration for Mw is intradermal, which has a limitation of administering 0.1 mL per injection and local injection site reaction. Intravenous (IV) administration of Mw has not been explored in COVID-19. We report the retrospective analysis of six critically ill COVID-19 patients who received Mw (IV). Patients and methods At baseline, all patients in this case series required O 2 supplementation, and their inflammatory biomarkers were elevated. All patients received 0.6 mL Mw (high-dose) in normal saline along with the standard-of-care treatment. Results After Mw administration, gradual improvement in O 2 requirement was observed and patients were discharged from the hospital with no mortality. A reduction in mean C-reactive protein (CRP) (51.48–18.52 mg/dL), interleukin-6 (IL-6) (260.22–14.47 pg/mL), and FiO 2 (81.67–43.33) was also observed. No side effects were observed with the use of Mw by IV route. Conclusion Use of 0.6 mL Mw by IV route in this case series was associated with decreased O 2 supplementation without any side effects in critically ill patients of COVID-19. How to cite this article Patel PS, Patel S, Shah V, Aswani V, Narwaria M. Early Experience of High-dose Intravenous Mycobacterium w in Critically Ill Patients of COVID-19. Indian J Crit Care Med 2021;25(9):1066–1068.

show abstract

Mycobacterium w administration for steroid resistant optic neuritis with long-term follow-up

Sudhalkar¹,

Khamar

2014

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Outcomes of toll-like receptors’ antagonism in steroid-resistant optic neuritis; a pilot study

Abstract: Mw appears to improve steroid resistant optic neuritis; future randomized clinical trials would help affirm this observation.

Cited by 5 publications

References 17 publications

Current options for the treatment of optic neuritis

Current options for the treatment of optic neuritis

Early Experience of High-dose Intravenous Mycobacterium w in Critically Ill Patients of COVID-19

Mycobacterium w administration for steroid resistant optic neuritis with long-term follow-up

Contact Info

Product

Resources

About